Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biotech Growth Trust (The)'s Enterprise Value is £316.1 Mil.
Biotech Growth Trust (The)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was £-4.8 Mil. Therefore, Biotech Growth Trust (The)'s EV-to-FCF for today is -65.37.
The historical rank and industry rank for Biotech Growth Trust (The)'s EV-to-FCF or its related term are showing as below:
LSE:BIOG'
s EV-to-FCF Range Over the Past 10 Years
Min: -251.87 Med: -86.87 Max: -29.31
Current: -65.37
During the past 13 years, the highest EV-to-FCF of Biotech Growth Trust (The) was -29.31. The lowest was -251.87. And the median was -86.87.
LSE:BIOG's EV-to-FCF is ranked worse than 100% of 936
companies
in the Asset Management industry
Industry Median: 14.495
vs LSE:BIOG: -65.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biotech Growth Trust (The)'s PE Ratio (TTM) for today is calculated as:
Biotech Growth Trust (The)'s share price for today is £15.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotech Growth Trust (The)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was £5.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biotech Growth Trust (The) EV-to-FCF Related Terms
Biotech Growth Trust (The) EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Biotech Growth Trust (The)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotech Growth Trust (The) EV-to-FCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Biotech Growth Trust (The)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biotech Growth Trust (The)'s EV-to-FCF falls into.
Biotech Growth Trust (The)'s current Enterprise Value is £316.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biotech Growth Trust (The)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was £-4.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotech Growth Trust (The) (LSE:BIOG) has a EV-to-FCF of -65.37 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biotech Growth Trust (The) and its competitors. According to the industry distribution chart, Biotech Growth Trust (The) ranks #999999 out of 936 companies in the Asset Management industry.
Is Biotech Growth Trust (The)'s EV-to-FCF too high?
Biotech Growth Trust (The)'s current EV-to-FCF is -65.37. Based on the distribution chart, Biotech Growth Trust (The) ranks #999999 out of 936 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, Biotech Growth Trust (The) has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Biotech Growth Trust (The)'s EV-to-FCF compare to BLK and BX?
According to the Asset Management industry distribution chart, Biotech Growth Trust (The) ranks #999999 out of 936 companies for EV-to-FCF. This places Biotech Growth Trust (The) in the lower half of its industry. The industry median EV-to-FCF is 14.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Asset Management company?
The median EV-to-FCF among Asset Management companies is 14.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biotech Growth Trust (The) and its competitors. For the Asset Management industry, the median EV-to-FCF is 14.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotech Growth Trust (The)'s current EV-to-FCF is -65.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotech Growth Trust (The) stock overvalued right now?
Biotech Growth Trust (The) (LSE:BIOG) has a current EV-to-FCF of -65.37. The current EV-to-FCF is -65.37. Biotech Growth Trust (The)'s overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biotech Growth Trust (The) (LSE:BIOG), the current EV-to-FCF is -65.37 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotech Growth Trust (The) PLC is an externally managed investment trust. Its business objective is to provide its investors with capital appreciation by investing in the biotechnology industry around the world.
39GF Score
Get the complete analysis for LSE:BIOG
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BIOG has been successfully added to your 
